It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
We present two new synthetic routes for bismuth ferrite harmonic nanoparticles (BiFeO3 HNPs). Both phase-pure and mixed phase BiFeO3 materials were produced after improvement of the solvent evaporation and sol-gel combustion routes. Metal nitrates with a series of dicarboxylic acids (tartronic, tartaric and mucic) were used to promote crystallization. We found that the longer the carbon backbone with a hydroxyl group attached to each carbon, the lower the annealing temperature. We also demonstrate that nanocrystals more readily formed at a given temperature by adding glycerol but to the detriment of phase purity, whereas addition of NaCl in excess with mucic acid promotes the formation of phase-pure, monocrystalline nanoparticles. This effect was possibly associated with a better dispersion of the primary amorphous precursors and formation of intermediate complexes. The nanoparticles have been characterized by XRD, TEM, ζ-potential, photon correlation spectroscopy, two-photon microscopy and Hyper-Rayleigh Scattering measurements. The improved crystallization leads to BiFeO3 HNPs without defect-induced luminescence and with a very high averaged second harmonic efficiency (220 pm/V), almost triple the efficiency previously reported. This development of simple, scalable synthesis routes which yield phase-pure and, crucially, monocrystalline BiFeO3 HNPs demonstrates a significant advance in engineering the properties of nanocrystals for bio-imaging and diagnostics applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Dublin 8, Ireland; CRANN Institute and AMBER centre, Trinity College Dublin, Dublin 2, Ireland; Univ. Savoie Mont Blanc, SYMME, Annecy, France
2 GAP – Biophotonics, Université de Genève, Genève 4, Switzerland
3 CRANN Institute and AMBER centre, Trinity College Dublin, Dublin 2, Ireland; School of Chemistry, Trinity College Dublin, Dublin 2, Ireland
4 Univ. Savoie Mont Blanc, SYMME, Annecy, France
5 Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Dublin 8, Ireland; CRANN Institute and AMBER centre, Trinity College Dublin, Dublin 2, Ireland; Department of Histology, Cytology and Embryology, First Moscow State Sechenov Medical University, Moscow, Russian Federation
6 Department of Clinical Medicine, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Dublin 8, Ireland; CRANN Institute and AMBER centre, Trinity College Dublin, Dublin 2, Ireland